Atazanavir: A novel azapeptide inhibitor of HIV-1 protease

Formulary

Volumn 38, Issue 12, 2003, Pages 691-702

  Wang, Fei ^a,b   Ross, Jack ^b,c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; ATENOLOL; ATORVASTATIN; CLARITHROMYCIN; CYCLOSPORIN; DIDANOSINE; DILTIAZEM; EFAVIRENZ; ETHINYLESTRADIOL; HISTAMINE H2 RECEPTOR ANTAGONIST; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NORETHISTERONE; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RAPAMYCIN; RIFABUTIN; RITONAVIR; SAQUINAVIR; SILDENAFIL; STAVUDINE; TACROLIMUS; TENOFOVIR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZIDOVUDINE;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; BLEEDING; CLINICAL TRIAL; CODON; CORONARY RISK; CROSS RESISTANCE; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TOLERABILITY; ENZYME INHIBITION; FLU LIKE SYNDROME; FOOD DRUG INTERACTION; GASTRITIS; GENE MUTATION; HEADACHE; HEART ARRHYTHMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; INFECTION; INSULIN RESISTANCE; JAUNDICE; LIPODYSTROPHY; MYOPATHY; NAUSEA; OBESITY; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PILL; QT INTERVAL; RASH; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT FAILURE; VIRUS LOAD; VOMITING;

EID: 0346752006     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the international AIDS Society-USA Panel. JAMA. 2002;288(2):222-235.
2. Goldschmidt RH, Dong BJ. Treatment of AIDS and HIV-related conditions-2002: Antiretroviral Therapy. J Am Board Fam Pract. 2002;15 (4):319-331.
3. Sanne I, Piliero P, Squires K, et al. Results of a Phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naïve subjects. J Acquir Immune Defic Syndr. 2003;32:18-29.
4. O'Mara EM, Smith J, Olsen SJ, et al. BMS-232632: Single and multiple oral dose safety and pharma cokinetic study in healthy volunteers. 6th Conference on Retroviruses and Opportunistic Infections; February 1999; Chicago, Ill. Abstract 604.
5. O'Mara E, Mummaneni V, Randall D, et al. BMS-232632: A summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy subjects. 7th Conference on Retroviruses and Opportunistic Infections; February 2000; San Francisco, Calif. Abstract 504.
6. Piliero P, Cahn P, Pantaleo G, et al. Atazanavir: a once daily protease inhibitor with a superior lipid profile: results of clinical trials beyond 48 weeks. 9th Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle, Wash. Abstract 706.
7. Haas DW, Zala C, Schrader S, et al, for the Protocol A1424-009 Study Group. Therapy with atazanavir plus saquinavir failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS. 2003; 17:1339-1349.
8. Gong Y, Robinson BS, Rose RE, et al, In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother. 2000;44(9):2319-2326.
9. Colonno RJ, Thiry A, Limoli K, et al. Activities of Atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother. 2003;47(4):1324-1333.
10. Robinson BS, Riccardi KA, Gong Y, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother. 2000;44(8):2093-2099.
11. Rabasseda X, Silvestre J, Castaner J. BMS-232632. Anti-HIV HIV-1 Protease Inhibitor. Drugs-of-the-Future. 1999;24(4):375-380.
12. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide based HIV proteinase inhibitors. Science. 1990;248:358-361.
13. De Clercq E. New anti-HIV agents and targets. Medicinal Res Rev. 2002;22(6):531-565.
14. Atazanavir BMS-232632. FDA Advisory Committee Briefing Document. Available at: http://www.fdaadvisorycommittee.com. Accessed June 9, 2003.
15. Colonno RJ, Rose R, Cianci C, et al. Emergence of Atazanavir resistance and maintenance of susceptibility to other PIs is associated with an 150L substitution in HIV protease. 10th Conference on Retroviruses and Opportunistic Infections; February 2003; Boston, Mass. Abstract 597.
16. Reyataz [package insert]. Princeton, NJ: Bristol-Meyers Squibb; June 2003.
17. Schnell T, Schmidt B, Moschik G, et al. Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples. AIDS. 2003; 17 (8):1258-1261.
18. Drusano GL, Bilello JA, Preston SL. Hollow-fiber evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. J Infect Dis. 2001; 183:1126-1129.
19. Sanne I, Cahn L, Percival P, et al. Comparative results (Phase II 48-week): BMS-232632, stavudine, lamuvidine as HAART for treatment-naïve HIV (+) patients (AI424-008). 41st Interscience Conference on Antimicrobial Agents Chemotherapy; December 2001; Chicago, Ill. Abstract 667.
20. Squires KE, Thiry A, Giordano M. Atazanavir (ATV) QD and Efavirenz (EFV) QD with fixed dose ZDV + 3TC: Comparison of antiviral efficacy and safety through week 24 (AI423-034). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2002; San Diego, Calif. Abstract H-1076.
21. Nieto-Cisneros L et al. Antiviral efficacy, metabolic changes and safety of atazanavir (ATV) versus lopinavir/ritonavir (LPV/RTV) in combination with two NRTIs in patients who have experienced virological failure with prior PI containing regimens:24 week results from BMS AI424-043. Antiviral Ther 2003;8(suppl 1):S212, abstract 117.
22. Badaro R, et al. Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in combination with tenofovir (TFV) and one NRTI in patients who have experienced virologic failure on multiple HAART regimens: 16 week results from BMS AI424-045. 2nd IAS Conference on HIV Pathogenesis and Treatment; July 2003; Paris, France. Abstract 118.
23. Murphy R, Pokrovsky V, Rozenbaum W, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or ATV: 108-week results of BMS study 008/044. 10th Conference on Retroviruses and Opportunistic Infections; February 2003; Boston, Mass. Abstract P555.
24. O'Mara EM, Mummaneni V, Randall D, et al. Assessment of the effect of uridine diphosphate glucuronosyltransferase (UDP-GT) 1A1 geno-type on indirect bilirubin elevations in healthy subjects dosed with BMS-232632 [abstract]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2000; Toronto, Ontario, Canada.
25. Piliero P, Cahn P, Pantaleo G, et al. Atazanavir: A once daily protease inhibitor with a superior lipid profile:results of clinical trials beyond week 48. 9th Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle,Wash. Abstract 706.
26. O'Mara E, Mummaneni V, Bifano M, et al. Pilot study of the interaction between BMS-232632 and ritonavir. 8th Conference on retroviruses and Opportunistic Infections; February 2002; Chicago, Ill. Abstract 740.
27. Agarwala S, et al. Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with ritonavir (RTV) in healthy subjects. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2002; San Diego, Calif. Abstract H-1716.
28. Preston S, Pililero P, O'Mara E, et al. Evaluation of the steady state interaction between atazanavir and efavirenz. 9th Conference on Retroviruses and Opportunistic infections; February 2002; Seattle, Wash. Abstract 443-W.
29. O'Mara E, Agarwala S, Randall D, et al. Steady state pharmacokinetic interaction study of atazanavir (ATV) with efavirenz (EFV) and ritonavir (RTV) in healthy subjects. 9th Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle, Wash. Abstract 444.
30. Taburet AM, et al. Pharmacokinetic parameters of Atazanavir/ritonavir when combined to tenofovir in HIV infected patients with multiple treatment failures: a sub-study of puzzle 2-ANRS 107 trial. 10th Conference on Retroviruses and Opportunistic Infections; February 2003; Boston, Mass. Abstract 537.
31. Mummaneni V, et al. Steady-state pharmacokinetic (PK) interaction of atazanavir (ATV) with lamuvidine (3TC) and zidovudine (ZDV) in healthy subjects. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2002; San Diego, Calif. Abstract H-1713.
32. Mummaneni V, et al. Steady-state (PK) interaction study of atazanavir (ATV) with clarithromycin (CLR) in healthy subjects. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2002; San Diego, Calif. Abstract H-1717.
33. Agarwala S, Mummaneni V, Randall D, et al. Pharmacokinetic (PK) effect of rifabutin (RIF) on atazanavir (ATV) with and without ritonavir (RTV) in healthy subjects. 9th Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle, Wash. Abstract 445.
34. O'Mara E, Randall D, Uderman H, et al. Steady state pharmacokinetic interaction study between BMS-232632 and ketoconazole in healthy subjects. 40th interscience Conference on Antimicrobial Agents and Chemotherapy; September 2000; Toronto, Ontario, Canada. Abstract 1646.